Gossamer Bio Completes $181M Convertible Note Exchange, Retains $19M in Debt
Event summary
- Gossamer Bio exchanged $181M of its 5.00% Convertible Senior Notes due 2027 for new 7.50% Convertible Senior Secured First Lien Notes due 2030 and equity securities.
- The exchange offer, initially requiring 98% participation, was lowered to 90.5% after $181M in notes were tendered by June 2, 2026.
- $18.9M in existing convertible notes remain outstanding post-exchange.
- The company eliminated restrictive covenants and certain events of default from the original notes via a supplemental indenture.
The big picture
Gossamer Bio's debt exchange reflects a strategic pivot to extend its financial runway amid the high-cost, high-risk biopharmaceutical development cycle. The move reduces near-term debt pressure but introduces new equity overhang. The biotech sector has seen increased restructuring activity as companies balance funding needs with investor scrutiny over capital efficiency.
What we're watching
- Debt Management
- How Gossamer Bio will deploy the remaining $18.9M in convertible notes and whether it can reduce debt further.
- Equity Dilution
- The impact of issuing up to 317.6M shares or prefunded warrants on existing shareholder value.
- Operational Focus
- Whether the financial restructuring will accelerate seralutinib development for pulmonary hypertension.
Related topics